FRIDAY JANUARY 17
08.30-09.00  Registration
09.00-09.30  Welcome and introduction
09.30-09.50  Inhibitor management
              – an era of new options (JA)
09.50-10.30  Immunology
              – mechanisms and value of tolerance (SLD)
10.30-11.00 Break
11.00-11.45  ITI therapy in severe hemophilia A
              over the lifespan (CEE)
11.45-12.15  Updates on new treatment protocols (RS)
12.15-13.00 Lunch
13.00-14.15  Faculty case debate (Faculty)
14.15-14.45  Emerging therapies in inhibitor management (CH)
14.45-15.15 Break
15.15-16.30  Interactive case discussion Part 1
              – participants’ cases
18:30-19:30  Octapharma Symposium
19.30 -      Dinner

SATURDAY JANUARY 18
08.30-09.00  ITI therapy in non-severe hemophilia A (PAH)
09.00-09.30  ITI therapy in hemophilia B (JA)
09.30-10.15  Acquired hemophilia
              – Similarities and differences in pathophysiology and clinical management (Faculty)
10.15-10.30 Break
10.30-11.00 Laboratory aspects for inhibitor management (JA/PAH)
11.00-12.15  Interactive case discussion Part 2
              – participants’ cases
12.15-13.00 Lunch
13.00-13.45  Interactive case discussion Part 3
              – participants’ cases
13.45-14.15  Examination
14.15-14.30  Course evaluation and concluding remarks

FACULTY
Jan Astermark, Malmö, Sweden (JA)
Pål André Holme, Oslo, Norway (PAH)
Carmen Escuriola Ettingshausen, Frankfurt, Germany (CEE)
Cedric Hermans, Brussels, Belgium (CH)
Sébastien Lacroix-Desmazes, Paris, France (SLD)
Robert F. Sidonio Jr., Altanta, USA (RS)